191 related articles for article (PubMed ID: 25189625)
21. Emerging drugs for small cell lung cancer--an update.
Metro G; Duranti S; Fischer MJ; Cappuzzo F; Crinò L
Expert Opin Emerg Drugs; 2012 Mar; 17(1):31-6. PubMed ID: 22288522
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.
Karam I; Jiang SY; Khaira M; Lee CW; Schellenberg D
Am J Clin Oncol; 2015 Feb; 38(1):51-4. PubMed ID: 23563211
[TBL] [Abstract][Full Text] [Related]
23. Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation.
Bonner JA; Willey CD; Yang ES; Dobelbower MC; Sanford LL; Bright SJ; Buchsbaum DJ; Raisch KP
Radiother Oncol; 2011 Oct; 101(1):183-9. PubMed ID: 21722984
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
[TBL] [Abstract][Full Text] [Related]
25. Survival of patients with small cell lung carcinoma in Taiwan.
Kuo YH; Lin ZZ; Yang YY; Shao YY; Shau WY; Kuo RN; Yang JC; Lai MS
Oncology; 2012; 82(1):19-24. PubMed ID: 22269348
[TBL] [Abstract][Full Text] [Related]
26. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?
Fischer B; Marinov M; Arcaro A
Cancer Treat Rev; 2007 Jun; 33(4):391-406. PubMed ID: 17368733
[TBL] [Abstract][Full Text] [Related]
27. Second-line treatments of small-cell lung cancers.
Baize N; Monnet I; Greillier L; Quere G; Kerjouan M; Janicot H; Vergnenegre A; Auliac JB; Chouaid C
Expert Rev Anticancer Ther; 2017 Nov; 17(11):1033-1043. PubMed ID: 28849951
[TBL] [Abstract][Full Text] [Related]
28. Advances in the treatment of small-cell lung cancer.
Kalemkerian GP
Semin Respir Crit Care Med; 2011 Feb; 32(1):94-101. PubMed ID: 21500128
[TBL] [Abstract][Full Text] [Related]
29. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.
Van Den Borg R; Leonetti A; Tiseo M; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2019 Jun; 19(6):461-471. PubMed ID: 31148500
[No Abstract] [Full Text] [Related]
30. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro.
Nakanishi Y; Mulshine JL; Kasprzyk PG; Natale RB; Maneckjee R; Avis I; Treston AM; Gazdar AF; Minna JD; Cuttitta F
J Clin Invest; 1988 Jul; 82(1):354-9. PubMed ID: 2839551
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?
Sun JM; Ahn MJ; Ahn JS; Um SW; Kim H; Kim HK; Choi YS; Han J; Kim J; Kwon OJ; Shim YM; Park K
Lung Cancer; 2012 Aug; 77(2):365-70. PubMed ID: 22579297
[TBL] [Abstract][Full Text] [Related]
32. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
33. Optimal drugs for second-line treatment of patients with small-cell lung cancer.
Rossi A; Sacco PC; Sgambato A; Casaluce F; Santabarbara G; Palazzolo G; Maione P; Gridelli C
Expert Opin Pharmacother; 2016; 17(7):969-76. PubMed ID: 26878692
[TBL] [Abstract][Full Text] [Related]
34. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.
Tarhini A; Kotsakis A; Gooding W; Shuai Y; Petro D; Friedland D; Belani CP; Dacic S; Argiris A
Clin Cancer Res; 2010 Dec; 16(23):5900-7. PubMed ID: 21045083
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.
Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Shimizu K; Imai H; Utsugi M; Iwasaki Y; Iijima H; Tsurumaki H; Yoshii A; Fueki N; Hisada T; Ishizuka T; Saito R; Mori M
Lung Cancer; 2010 Jul; 69(1):99-104. PubMed ID: 19853960
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
[TBL] [Abstract][Full Text] [Related]
38. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer.
Yee D; Butts C; Reiman A; Joy A; Smylie M; Fenton D; Chu Q; Hanson J; Roa W
Radiother Oncol; 2012 Feb; 102(2):234-8. PubMed ID: 21930323
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer.
Shibata T; Kokubu A; Tsuta K; Hirohashi S
Cancer Lett; 2009 Oct; 283(2):203-11. PubMed ID: 19394761
[TBL] [Abstract][Full Text] [Related]
40. Outcomes in recurrent small-cell lung cancer after one to four chemotherapy lines: a retrospective study of 300 patients.
Nagy-Mignotte H; Guillem P; Vignoud L; Coudurier M; Vesin A; Bonneterre V; Toffart AC; Sakhri L; Brambilla C; Brambilla E; Timsit JF; Moro-Sibilot D;
Lung Cancer; 2012 Oct; 78(1):112-20. PubMed ID: 22795703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
